Joseph B. Gastala

Joseph B. Gastala

Auto-generated profile, based on publicly available information

Joseph B. Gastala

From the Division of Immunotherapy, Department of Medicine (R.K.B., X.H., C.B.), and Departments of Neurology (R.B.), Radiology (J.G.), and Preventive Medicine (B.J., I.H.), Northwestern University Feinberg School of Medicine, Chicago, IL; and the Departments of Neurology (J.J., S.J.P.) and Laboratory Medicine and Pathology (J.J., J.P.F., S.J.P.) and Center for Multiple Sclerosis and Autoimmune Neurology (S.J.P.), Mayo Clinic College of Medicine, Rochester, MN

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2006 in Science
Verified
Journal Article
Closed access
PDF file
DHDaniel A. Heller
Daniel A. Heller
EJEsther S. Jeng
Esther S. Jeng
TYTsun-Kwan Yeung
Tsun-Kwan Yeung
BMBrittany M. Martinez
Brittany M. Martinez
AMAnthonie E. Moll
Anthonie E. Moll
MSMichael S. Strano
Michael S. Strano
The transition of DNA secondary structure from an analogous B to Z conformation modulates the dielectric environment of the single-walled carbon nanotube (SWNT) around which it is adsorbed. The SWNT band-gap fluorescence undergoes a red shift when an encapsulating 30-nucleotide oligomer is exposed to counter ions that screen the charged backbone. The transition is thermodynamically identical for DNA on and off the nanotube, except that the propagation length of the former is shorter by five-sixths. The magnitude of the energy shift is described by using an effective medium model and the DNA geometry on the nanotube sidewall. We demonstrate the detection of the B-Z change in whole blood, tissue, and from within living mammalian cells.

17 February 2006 in Nano Letters
Verified
Journal Article
Closed access
EJEsther S. Jeng
Esther S. Jeng
AMAnthonie E. Moll
Anthonie E. Moll
ARAmanda C. Roy
Amanda C. Roy
JGJoseph B. Gastala
Joseph B. Gastala
MSMichael S. Strano
Michael S. Strano

29 October 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
RBRichard Burt
Richard Burt
RBRoumen Balabanov
Roumen Balabanov
XHXiaoqiang Han
Xiaoqiang Han
CBCarol Burns
Carol Burns
JGJoseph Gastala
Joseph Gastala
SPSean J. Pittock
Sean J. Pittock
Objective To determine if autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) could be a salvage therapy for neuromyelitis optica spectrum disorder (NMOSD). Methods Thirteen patients were enrolled in a prospective open-label cohort study (11 NMOSD aquaporin-4–immunoglobulin G [AQP4-IgG]–positive, 1 NMOSD without AQP4, and 1 NMOSD AQP4-IgG-positive with neuropsychiatric systemic lupus erythematosus [SLE]). Following stem cell mobilization with cyclophosphamide (2 g/m2) and filgrastim, patients were treated with cyclophosphamide (200 mg/kg) divided as 50 mg/kg IV on day −5 to day −2, rATG (thymoglobulin) given IV at 0.5 mg/kg on day −5, 1 mg/kg on day −4, and 1.5 mg/kg on days −3, −2, and −1 (total dose 6 mg/kg), and rituximab 500 mg IV on days −6 and +1. Unselected peripheral blood stem cells were infused on day 0. AQP4-IgG antibody status was determined by Clinical Laboratory Improvement Amendments–validated ELISA or flow cytometry assays. Cell-killing activity was measured using a flow cytometry–based complement assay. Results Median follow-up was 57 months. The patient with coexistent SLE died of complications of active lupus 10 months after HSCT. For the 12 patients with NMOSD without other active coexisting autoimmune diseases, 11 patients are more than 5 years post-transplant, and 80% are relapse-free off all immunosuppression (p < 0.001). At 1 and 5 years after HSCT, Expanded Disability Status Scale score improved from a baseline mean of 4.4 to 3.3 (p < 0.01) at 5 years. The Neurologic Rating Scale score improved after HSCT from a baseline mean of 69.5 to 85.7 at 5 years (p < 0.01). The Short Form–36 health survey for quality of life total score improved from mean 34.2 to 62.1 (p = 0.001) at 5 years. In the 11 patients whose baseline AQP4-IgG serostatus was positive, 9 patients became seronegative by the immunofluorescence or cell-binding assays available at the time; complement activating and cell-killing ability of patient serum was switched off in 6 of 7 patients with before and after HSCT testing. Two patients remained AQP4-IgG-seropositive (with persistent complement activating and cell-killing ability) and relapsed within 2 years of HSCT. No patient with seronegative conversion relapsed. Conclusion Prolonged drug-free remission with AQP4-IgG seroconversion to negative following nonmyeloablative autologous HSCT warrants further investigation.

13 June 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
VHVirginia Boyce Hill
Virginia Boyce Hill
CCC.Z. Cankurtaran
C.Z. Cankurtaran
BLB.P. Liu
B.P. Liu
THT.A. Hijaz
T.A. Hijaz
MNM. Naidich
M. Naidich
AKA.W. Korutz
A.W. Korutz
SUMMARY: Functional MR imaging is being performed with increasing frequency in the typical neuroradiology practice; however, many readers of these studies have only a limited knowledge of the functional anatomy of the brain. This text will delineate the locations, anatomic boundaries, and functions of the cortical regions of the brain most commonly encountered in clinical practice—specifically, the regions involved in movement and language.